Skip to main content
. 2014 Oct 30;13(20):3191–3201. doi: 10.4161/15384101.2014.950126

Figure 4.

Figure 4.

CDK2i treatment of MDA-MB-231 alters activity of transcription factors associated with oncogenic processes. MDA-MB-231 cells were transduced with TF reporters and treated with CDK2i. Bioluminescence was normalized to TA control at (A) 1, 2, and 4 hours (early timepoints) and (B) at 1, 3, and 6 d (late timepoints).